Paget's disease: Acquired resistance to one aminobisphosphonate with retained response to another

Journal of Bone and Mineral Research

Volumn 14, Issue SUPPL. 2, 1999, Pages 79-84

  Gutteridge, D H ^a,c   Ward, L C ^a   Stewart, G O ^d   Retallack, R W ^a   Will, R K ^e   Prince, R L ^a,c   Criddle, A ^a   Bhagat, C I ^b   Stuckey, B G A ^a   Price, R I ^a   Kent, G N ^b   Faulkner, D L ^a   Geelhoed, E ^c   Gan, S K ^a   Vasikaran, S ^e  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b Div of Microbiol and Infect Dis   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d FREMANTLE HOSPITAL   (Australia)

^e ROYAL PERTH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CREATININE; DEOXYPYRIDINOLINE; ETIDRONIC ACID; HYDROXYPROLINE; PAMIDRONIC ACID;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; BONE TURNOVER; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE URINE LEVEL; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; HYDROXYPROLINE URINE LEVEL; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PAGET BONE DISEASE; RADIODIAGNOSIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; THERAPY RESISTANCE; TREATMENT OUTCOME; URINARY EXCRETION;

EID: 0032880957     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.5650140216     Document Type: Conference Paper

References (16)

1. Khairi MRA, Altman RD, De Rosa GP, Zimmerman J, Schenk RK, Johnston CC 1977 Sodium etidronate in the treatment of Paget's disease of bone. Ann Intern Med 87:656-663.
2. Altman RD 1985 Long-term follow-up of therapy with intermittent etidronate disodium in Paget's disease of bone. Am J Med 79:583-592.
3. Patel S, Stone MD, Coupland C, Hosking DJ 1993 Determinants of remission of Paget's disease of bone. J Bone Miner Res 8:1467-1473.
4. Gutteridge DH, Retallack RW, Ward LC, Stuckey BGA, Stewart GO, Prince RL, Kent GN, Bhagat CI, Price RI, Thompson RI, Nicholson GC 1996 Clinical, biochemical, hematologic and radiographic responses in Paget's disease following intravenous pamidronate disodium: A 2 year study. Bone 19:387-394.
5. Luckman SP, Hughes DE, Coxon FP, Russell RGG, Rogers MJ 1998 Nitrogen containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13:581-589.
6. Frith JC, Mönkkönen J, Blackburn GM, Russell RGG, Rogers MJ 1997 Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(β,γ-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 12:1358-1367.
7. Johnston CC, Khairi MRA, Meunier PJ 1980 Use of etidronate (EHDP) in Paget's disease of bone. Arthritis Rheum 23:1172-1176.
8. Roux C, Gennari C, Farrerons J, Devogelaer JP, Mulder H, Kruse HP, Picot C, Titeux L, Reginster JY, Dougados M 1995 Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. Arthritis Rheum 38:851-858.
9. Siris E, Weinstein RS, Altman R, Conte JM, Favus M, Lombardi A, Lyles K, McIlwain H, Murphy WA, Reda C, Rude R, Seton M, Tiegs R, Thompson D, Tucci JR, Yates AJ, Zimering M 1996 Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab 81:961-967.
10. Yates AJP, Percival RC, Gray RES, Atkins RM, Urwin GH, Hamdy NAT, Preston CJ, Beneton MNC, Russell RGG, Kanis JA 1985 Intravenous clodronate in the treatment of Paget's disease of bone. Lancet 1:1474-1477.
11. Harinck HIJ, Bijvoet OLM, Blanksma HJ, Dahlinghaus-Nienhuys PJ 1987 Efficacious management with aminobisphosphonate (APD) in Paget's disease of bone. Clin Orthop 217:79-98.
12. Cundy T, Wattie D, King AR 1996 High-dose pamidronate in the management of resistant Paget's disease. Calcif Tissue Int 58:6-8.
13. Stewart GO, Gutteridge DH, Price RI, Ward LC, Retallack RW, Prince RL, Stuckey BGA, Kent GN, Bhagat CI, Dhaliwal SS 1999 Prevention of appendicular bone loss in Paget's disease following treatment with intravenous pamidronate disodium. Bone 24:139-144.
14. Randall AG, Kent GN, Garcia-Webb P, Bhagat CI, Pearce DJ, Gutteridge DH, Prince RL, Stewart GO, Stuckey BGA, Will RK, Retallack RW, Price RI, Ward LC 1996 Comparison of biochemical markers of bone turnover in Paget disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline cross-links. J Bone Miner Res 11:1176-1184.
15. Delmas PD, Chapuy MC, Edouard C, Meunier P 1987 Beneficial effects of aminohexane diphosphonate in patients with Paget's disease of bone resistant to sodium etidronate. Am J Med 83:276-282.
16. Siris ES, Chines AA, Altman RD, Brown JP, Johnston CC, Lang R, McClung MR, Mallette LE, Miller PD, Ryan WG, Singer FR, Tucci JR, Eusebio RA, Bekker PJ 1998 Risedronate in the treatment of Paget's disease of bone: An open label multicenter study. J Bone Miner Res 13:1032-1038.